Tue, 1/16/24: 12:00 AM EST
Fri, 1/15/27: 12:00 AM EST
This enduring material takes a deeper dive into one of the four key priorities in the FDA's Overdose Prevention Framework: encouraging harm reduction. It focuses on the Agency's vision as it relates to encouraging harm reduction, including expanding availability and access to lifesaving overdose reversal products. The discussion focuses on the impacts of the recent approvals of nonprescription naloxone nasal spray as well as prescription nalmefene nasal spray, another medication for opioid overdose.
- Explain the implications of over-the-counter (OTC) approval of naloxone nasal spray and what this means for harm reduction in opioid users
- Discuss the transition period regarding nonprescription naloxone nasal spray and when consumers can anticipate this product on OTC shelves
- Outline important information regarding the recent approval of prescription nalmefene nasal spray
Review the Activity Announcement for additional details: Announcement Form